A comparison of cancer stage at diagnosis and treatment initiation between enrollees in an urban HIV clinic and SEER
| Autor: | Anthony T Fojo, Catherine R. Lesko, Geetanjali Chander, Richard D. Moore, Corinne E. Joshu, Keri L. Calkins, Kala Visvanathan, Bryan Lau |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Population Human immunodeficiency virus (HIV) HIV Infections medicine.disease_cause Article 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Neoplasms Epidemiology medicine Humans 030212 general & internal medicine Stage (cooking) education Aged Neoplasm Staging Aged 80 and over education.field_of_study Hematology business.industry Public health Cancer stage Cancer Middle Aged medicine.disease Oncology 030220 oncology & carcinogenesis Female business SEER Program |
| Zdroj: | Cancer Causes Control |
| Popis: | PURPOSE: A comparison of stage at cancer diagnosis and cancer treatment rates between people with HIV (PWH) and the general US population is needed to identify any disparities by HIV status. METHODS: We compared 236 PWH in clinical care diagnosed with cancer from 1997 to 2014 to a sample from NCI’s Surveillance, Epidemiology and End Results (SEER) Program, presumed to be HIV negative. We performed G-computation using random forest methods to estimate stage and treatment percent differences (PD) by HIV. We conducted sensitivity analyses among non-AIDS-defining cancers (NADC), by sex and by CD4 ≤ 200 or > 200 cells/mm(3). RESULTS: PWH were less likely to be diagnosed at localized stage (PD = − 16%; 95% CI − 21, − 11) and more likely to be diagnosed at regional stage (PD = 14%; 95% CI 8, 19) than those in SEER. Cancer treatment rates were 13% lower among PWH as compared to SEER (95% CI − 18, − 8). The difference in percent receiving cancer treatment was more pronounced for those with lower CD4 at cancer diagnosis (PD −15%; 95% CI − 27, − 6). Lower treatment rates were observed among NADC, males, and women with CD4 ≤ 200. CONCLUSION: Cancer care for PWH could be improved by diagnosis at earlier stages and increasing rates of cancer treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|